Posts
January 10 2024
Client Alert: U.S. Department of Labor Announces Final Rule Regarding Classification of Independent Contractors
Yesterday, the U.S. Department of Labor (“DOL”) unveiled the details of a long-awaited final rule clarifying its guidance on determining whether a worker should be classified as an “employee” or “independent contractor” under the Fair Labor Standards Act (“FLSA”) (the “Final Rule”). The Final Rule takes effect March 11, 2024.
Click here to read the alert.
January 10 2024
PolyPid Ltd. announced the closing of its Private Placement in the amount of $16,200,000. EG&S acted as counsel to the Placement Agent.
January 09 2024
eFFECTOR Therapeutics, Inc. announced the closing of its Registered Direct offering in the amount of $15,000,000. EG&S acted as counsel to the Placement Agent.
January 09 2024
SurgePays, Inc. (Nasdaq: SURG), a multiproduct company focused on the underbanked and underserved, announced that it has closed the asset purchase agreement to acquire the software development and point-of-sale equipment and operations of DNR Business Solutions Inc. d/b/a ClearLine Mobile. ClearLine Mobile produces a touchscreen display, positioned by the cash register, that is integrated into the SurgePays software platform and markets SurgePays products 24/7 from a central server. SurgePays can advertise its entire suite of products and services while utilizing the POS device for transactions. The transactions is valued at approximately $2,500,000. EGS acted as counsel to SurgePays, Inc.
January 08 2024
Aditxt, Inc. announced the closing of its Private Placement in the amount of $6,000,000. EG&S acted as counsel to the Placement Agent.
January 08 2024
Gevo Inc. announced the commencement of its At The Market Offering in the amount of $500,000,000. EG&S acted as counsel to the Sales Agent.
January 07 2024
SeaStar Medical Holding Corporation announced the closing of its Registered Direct offering in the amount of $9,000,000. EG&S acted as counsel to the Placement Agent.
January 06 2024
eFFECTOR Therapeutics, Inc. announced the closing of its Registered Direct offering in the amount of $15,000,000. EG&S acted as counsel to the Placement Agent.